Prospective Head-to-Head Comparison of Fibroblast Imaging with [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in Unclear Hepatic Lesions.

Susanne Stanzel,Tina Nazerani-Zemann,Friedrich Weitzer,Elisabeth Plhak,Ariane Aigelsreiter,Thomas Kuenzer,Herbert Kvaternik,Jasminka Igrec,Jan Bucerius
{"title":"Prospective Head-to-Head Comparison of Fibroblast Imaging with [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in Unclear Hepatic Lesions.","authors":"Susanne Stanzel,Tina Nazerani-Zemann,Friedrich Weitzer,Elisabeth Plhak,Ariane Aigelsreiter,Thomas Kuenzer,Herbert Kvaternik,Jasminka Igrec,Jan Bucerius","doi":"10.2967/jnumed.125.271597","DOIUrl":null,"url":null,"abstract":"This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [68Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. Results: Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (n = 162) and radiologic examinations (n = 129). On the basis of visual analysis, 44 patients showed elevated [68Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [18F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [68Ga]Ga-FAPI-46 PET/CT than in [18F]FDG PET/CT (P < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [18F]FDG uptake alone. [68Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [18F]FDG PET/CT. SUVmax for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [68Ga]Ga-FAPI-46 PET/CT than on [18F]FDG PET/CT (all P < 0.05). Conclusion: [68Ga]Ga-FAPI-46 PET/CT is superior to [18F]FDG PET/CT in characterizing unclear hepatic lesions.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.271597","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [68Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. Results: Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (n = 162) and radiologic examinations (n = 129). On the basis of visual analysis, 44 patients showed elevated [68Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [18F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [68Ga]Ga-FAPI-46 PET/CT than in [18F]FDG PET/CT (P < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [18F]FDG uptake alone. [68Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [18F]FDG PET/CT. SUVmax for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [68Ga]Ga-FAPI-46 PET/CT than on [18F]FDG PET/CT (all P < 0.05). Conclusion: [68Ga]Ga-FAPI-46 PET/CT is superior to [18F]FDG PET/CT in characterizing unclear hepatic lesions.
[68Ga]Ga-FAPI-46 PET/CT与[18F]FDG PET/CT对不明确肝病变成纤维细胞成像的前瞻性头部比较
本研究旨在比较68Ga标记的成纤维细胞活化蛋白抑制剂46 ([68Ga]Ga-FAPI-46) PET/CT与[18F]FDG PET/CT对不明确肝病变的表现。方法:对59例疑似肝内病变患者进行前瞻性评价。肿瘤放射学特征、病理或随访检查作为与PET扫描相关的参考方法进行评估。在[68Ga]Ga-FAPI-46 PET/CT上进行额外的腹部动态成像。我们测量了SUV并计算了两次扫描的肿瘤与肝脏的背景比。从16例肝细胞癌/胆管癌、肝外恶性肿瘤或良性病变的肝内转移(IMs)患者的样本中,通过免疫组织化学评估成纤维细胞激活蛋白的表达。结果:经组织学检查(n = 162)和影像学检查(n = 129)确定原发性肝胆肿瘤(PHBTs),其中肝细胞癌76例22例,胆管癌24例5例,IMs 16例136例,良性病变16例55例。目视分析,44例患者出现[68Ga]Ga-FAPI-46摄取升高(敏感性100%,特异性94%),32例患者出现[18F]FDG-avid病变(敏感性70%,特异性88%)。[68Ga]Ga-FAPI-46 PET/CT的敏感性显著高于[18F]FDG PET/CT (P < 0.001)。14例(87.5%)患者中50例(90.9%)良性肝脏病变在PET扫描上均可忽略摄取,1例患者中1例(1.8%)良性肝脏病变单独显示FDG摄取增加[18F]。[68Ga]Ga-FAPI-46 PET/CT显示肝外原发肿瘤10例,[18F]FDG PET/CT显示3例。[68Ga]Ga-FAPI-46 PET/CT上phbt的SUVmax、最大瘤背景比和平均瘤背景比均显著高于[18F]FDG PET/CT(均P < 0.05)。结论:[68Ga]Ga-FAPI-46 PET/CT对肝脏模糊病变的诊断优于[18F]FDG PET/CT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书